3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
1
Lymphoid
1
Genitourinary
1
CNS
1
Conditions
Sarcoma
2
Wilms Tumor
1
Triple Negative Breast Neoplasms
1
Sarcoma, Synovial
1
Sarcoma, Ewing
1
Rhabdomyosarcoma
1
Rhabdoid Tumor
1
Recurrence
1
Prostatic Neoplasms
1
Ovarian Neoplasms
1
Osteosarcoma
1
Neuroectodermal Tumors, Primitive
1
Neuroblastoma
1
Neoplasms, Neuroepithelial
1
Neoplasms
1
Medulloblastoma
1
Lymphoma, Non-Hodgkin
1
Lymphoma
1
Hodgkin Disease
1
Gliosarcoma
1
Glioma
1
Glioblastoma
1
Esophageal Neoplasms
1
Ependymoma
1
Diffuse Intrinsic Pontine Glioma
1
Desmoplastic Small Round Cell Tumor
1
Colorectal Neoplasms
1
Carcinoma, Non-Small-Cell Lung
1
Interventions
Cyclophosphamide
42
fludarabine phosphate
33
Peripheral Blood Stem Cell Transplantation
32
Mycophenolic Acid
26
Whole-Body Irradiation
23
Cyclosporine
23
Busulfan
23
Radiotherapy
19
Filgrastim
19
Antilymphocyte Serum
19
Tacrolimus
16
Melphalan
16
Methotrexate
12
Methylprednisolone
10
Cord Blood Stem Cell Transplantation
10
Etoposide
8
Thiotepa
6
sargramostim
5
fludarabine
5
Therapeutics
5
aldesleukin
4
Sirolimus
4
Cytarabine
4
Polymerase Chain Reaction
3
Paclitaxel
3
Granulocyte Colony-Stimulating Factor
3
Carmustine
3
Amplified Fragment Length Polymorphism Analysis
3
Alemtuzumab
3
thymoglobulin
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Hodgkin Disease
×
CLR1404
×
Sarcoma
×
Clear all
NCT03478462
2026-03-18
CLOVER-2
Cellectar Biosciences, Inc.
Phase 1
Active not recruiting
30 enrolled